The study of effects of Canagliflozin ON T2DM patients' glycemic value Reduction and On Lowering dosage of insulin therapy
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000018085
- Lead Sponsor
- niversity of Occupational and Environmental Health
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 58
Not provided
For those who fall into any of the following criteria are excluded from the study: 1. Patients who use SGLT2, GLP-1, SU, or glinide within last 12 weeks just before giving their consent 2. Patients who are dehydrated 3. Patients who are on emulgent 4. Patients who are hospitalized as a result of sick day 5. Patients with serious infection or injury, or perioperative patients 6. Patients with a history of myocardial infarction, angina, stroke, or cerebral infarction 7. Patients with moderate renal dysfunction (eGFR<45mL/min/1.73m2) 8. Patients with severe liver functional impairment (AST>=100 IU/L) 9. Patients with moderate to severe heart failure as class 3 or worse based on the New York Heart Association (NYHA) Functional Classification 10. Patients with urinary tract infection, or genital infection 11. Patients with a malignant tumor or have a history of malignant tumor (exceptions: those are not on medication for malignant tumor, and have no recurrence of the disease so far and without recurrence risks during this study are allowed to participate) 12. If canagliflozin is prohibited to use 13. Patients with other conditions that are judged by a physician to be inappropriate to this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change of the amount of insulin dosage (unit) per day from baseline to the 2nd week
- Secondary Outcome Measures
Name Time Method